However, they found that using a non-tumor cell-specific glutaminase inhibitor in combination with anti-PD-1 severely impeded CD8+ T cell clonal expansion and anti-tumor functions, and anti-PD-1 efficacy was dependent on intact CD8+ T cell glutaminase activity[189]. Here, PDCD1 is linked to neoplasm.